Skip to main content

AbbVie vs Eli Lilly: Founders, CEOs and History

AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks.

Company facts

AbbVie

Founded
2013
Headquarters
North Chicago, Illinois
Current CEO
Robert A. Michael
Employees
57,000

Eli Lilly

Founded
1876
Headquarters
Indianapolis, Indiana
Current CEO
David A. Ricks
Employees
50,000

Founders

AbbVie

  • Abbott Laboratories (spin-off origin)

    Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.

AbbVie founders in full

Eli Lilly

  • Colonel Eli Lilly

    Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.

Eli Lilly founders in full

CEOs and their tenures

AbbVie

  1. Richard A. Gonzalez2013–2024

    Founding Chairman and Chief Executive Officer

    Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.

    Source
  2. Robert A. Michael2024–present

    Chairman and Chief Executive Officer

    Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.

    Source
AbbVie CEO history in full

Eli Lilly

  1. Randall L. Tobias1993–1998

    Chairman and Chief Executive Officer

    Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.

    Source
  2. Sidney Taurel1998–2008

    Former Chair and CEO

    Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.

    Source
  3. John C. Lechleiter2008–2016

    Chairman, President and CEO

    Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.

    Source
  4. David A. Ricks2017–present

    Chair and Chief Executive Officer

    Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.

    Source
Eli Lilly CEO history in full

Timeline: AbbVie and Eli Lilly side by side

  1. 1876Eli Lilly

    Eli Lilly Founded

    Colonel Eli Lilly founds the company in Indianapolis.

  2. 1923Eli Lilly

    Insulin Commercialization

    Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.

  3. 1950Eli Lilly

    Antibiotic Expansion

    The company expands through antibiotics and broader prescription medicines.

  4. 1982Eli Lilly

    Humulin Approved

    Lilly introduces Humulin, one of the first recombinant DNA human insulin products.

  5. 2013AbbVie

    AbbVie Launches as an Independent Company

    AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.

  6. 2015AbbVie

    Pharmacyclics Acquisition Completed

    AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.

  7. 2017Eli Lilly

    David Ricks Becomes CEO

    David A. Ricks becomes Chair, President, and CEO.

  8. 2019AbbVie

    Skyrizi Receives Initial U.S. Approval

    The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.

  9. 2019AbbVie

    Rinvoq Receives Initial U.S. Approval

    The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.

  10. 2019Eli Lilly

    Loxo Oncology Acquired

    Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.

  11. 2020AbbVie

    Allergan Acquisition Completed

    AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.

  12. 2022Eli Lilly

    Mounjaro Approved

    Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.

  13. 2023AbbVie

    U.S. Humira Biosimilar Competition Begins

    Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.

  14. 2023Eli Lilly

    Zepbound Approved

    Zepbound receives U.S. approval for chronic weight management.

  15. 2024AbbVie

    ImmunoGen Acquisition Completed

    AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.

  16. 2024AbbVie

    Robert A. Michael Becomes CEO

    Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.

  17. 2024AbbVie

    Cerevel Therapeutics Acquisition Completed

    AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.

  18. 2025AbbVie

    Robert A. Michael Becomes Chairman

    Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.

  19. 2025AbbVie

    FY2025 Revenue Reaches $61.160 Billion

    AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

  20. 2025Eli Lilly

    Revenue Reaches $65.179B

    Lilly reports $65.179B in 2025 revenue and $20.640B in net income.

  21. 2025Eli Lilly

    First $1 Trillion Drugmaker

    Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.

  22. 2026AbbVie

    Q1 2026 Revenue Reaches $15.002 Billion

    AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.

  23. 2026Eli Lilly

    Foundayo Approved

    FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.

Acquisitions

AbbVie

  • ImmunoGen, Inc.2024$10.1B
  • Cerevel Therapeutics2024$8.7B
  • Allergan plc2020$63B
  • Pharmacyclics, Inc.2015$21B
All AbbVie acquisitions

Eli Lilly

  • Morphic Holding2024$3.2B
  • POINT Biopharma2023$1.4B
  • Prevail Therapeutics2021$1B
  • Loxo Oncology2019$8B
  • Elizabeth Arden1971Undisclosed
All Eli Lilly acquisitions

Questions about AbbVie vs Eli Lilly

Who is the CEO of AbbVie Inc. and Eli Lilly and Company?

AbbVie Inc. is led by Robert A. Michael and Eli Lilly and Company is led by David A. Ricks. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was AbbVie Inc. founded vs Eli Lilly and Company?

Eli Lilly and Company was founded in 1876 — 137 years before AbbVie Inc., which was founded in 2013. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..

How many employees does AbbVie Inc. have compared to Eli Lilly and Company?

AbbVie Inc. employs approximately 57,000 people, while Eli Lilly and Company employs approximately 50,000. AbbVie Inc. has the larger workforce at 57,000 employees, compared to Eli Lilly and Company's 50,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are AbbVie Inc. and Eli Lilly and Company headquartered?

Both AbbVie Inc. and Eli Lilly and Company are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded AbbVie Inc. and Eli Lilly and Company?

AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Eli Lilly and Company was founded by Colonel Eli Lilly.

Which company has a longer operating history — AbbVie Inc. or Eli Lilly and Company?

Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Eli Lilly overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.